What Greer Laboratories does

Stallergenes Greer, operating in the United States under the Greer Laboratories heritage (founded 1904, headquartered in Lenoir, North Carolina), is a global biopharmaceutical company specializing in allergen immunotherapy (AIT) for the diagnosis and treatment of allergies. The company develops, manufactures, and commercializes allergen extracts and related supplies from a single North Carolina production facility, employing 251–500 people. Its product portfolio is organized into three core lines: Human Allergy (personalized allergen extracts and supplies for patient diagnosis and immunotherapy), Veterinary Allergy (testing and allergen-specific immunotherapy for canine, feline, and equine patients), and Source Materials (customized raw allergenic materials supplied to other diagnostics and therapeutics manufacturers).

The underlying technology is allergen extract formulation and immunotherapy, a regulated pharmaceutical discipline in which patients are desensitized through controlled, escalating exposure to specific allergens. The North Carolina facility serves as the integrated development and manufacturing site, and the company extends credibility through digital engagement tools including a US pollen allergy map and a virtual tour of its production operations. Stallergenes Greer self-describes as a "leading global biopharmaceutical company" in AIT, supported by a 120-year operating history.

The business model is a direct-to-healthcare-professional sales motion: US allergists, immunologists, and veterinarians order through dedicated, persona-segmented websites (stagrallergy.com, stagrveterinaryallergy.com, stagrsourcematerials.com), with compliance gating and prescribing information surfaced alongside order functionality. Pricing is not publicly disclosed and is contracted per order with the practicing HCP. Revenue streams are product sales across the three segments, with no subscription, licensing, or platform model indicated. Customer base is horizontal and fragmented across independent practices, with no publicly disclosed anchor accounts or enterprise contracts, which implies low account-level concentration but segment-level dependence on US allergist prescribing behavior.

Name

Greer Laboratories

Legal name

Stallergenes Greer

Website

https://greerlabs.com

Company type

Private

Founded year

1904

Operating status

Operating

Headcount range

251–500 employees

Short description

Stallergenes Greer (US: Greer Laboratories) is a North Carolina-based biopharmaceutical company founded in 1904 that develops, manufactures, and sells allergen immunotherapy extracts and supplies for human and veterinary allergy treatment, plus raw allergenic source materials, selling directly to US healthcare professionals.

Ownership category

akta.pro rank

Product category

Allergen Immunotherapy Biopharmaceuticals

NAICS

Medical Laboratories (621511)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

akta.pro secondary industries

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF), Autoimmune & Allergy Diagnostics (HLAAALAK), Veterinary Vaccine & Biologics Distributors (HLAMAIAC)

Keywords

• Allergen immunotherapy products
• Allergy diagnostic extracts
• Veterinary allergy treatment
• Allergenic source materials
• Biopharmaceutical allergy solutions

Headquarters

HQ city

Lenoir

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

1. Allergen Immunotherapy Products: Sale of allergen immunotherapy products including extracts for diagnosis and treatment of allergies in humans and animals

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Greer Laboratories (operating as Stallergenes Greer) is a biopharmaceutical company that develops, manufactures, and commercializes allergen immunotherapy (AIT) products. Its portfolio includes allergen extracts and supplies for personalized treatment of human allergies, veterinary allergy testing and immunotherapy products for canine, feline, and equine patients, and customized allergenic source materials for diagnostics and therapeutics.

Product overview

Stallergenes Greer is a biopharmaceutical company offering a portfolio of allergen immunotherapy (AIT) products and services for allergy diagnosis and treatment. The product portfolio consists of three core offerings: Human Allergy (allergen extracts and supplies for patient treatment), Veterinary Allergy (testing and immunotherapy for companion animals), and Source Materials (raw allergenic materials). The company operates from a North Carolina facility and serves the US healthcare market.

Differentiator

Problem solved

Functional benefit

Brands

• Human Allergy: Allergen extracts and supplies for personalized patient allergy treatment
• Veterinary Allergy
• Source Materials

Products and services

• Human Allergy Allergen extracts and supplies for personalized patient allergy treatment, used in diagnosis and treatment of human allergies through allergen immunotherapy (AIT). Targeted at allergists, immunologists, and other healthcare professionals in the United States.
• Veterinary Allergy Allergy testing and treatment products for canine, feline, and equine patients, providing allergen-specific immunotherapy for animal allergies. Targeted at veterinary practitioners.
• Source Materials Customized allergenic source materials providing a dependable supply of quality raw materials for allergy diagnostic and treatment products. Targeted at customers requiring customized support and reliable allergenic source materials.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• HAL Allergy: European allergen immunotherapy company offering diagnostic and therapeutic allergen extracts across multiple European geographies, comparable in modality and customer segments.
• Leti Pharma: European manufacturer specializing in allergy diagnostics and allergen-specific immunotherapy products; competes most directly in source materials and human extract categories.
• ALK-Abelló: Danish-listed global leader in allergy immunotherapy (SLIT tablets, subcutaneous extracts, diagnostics), the most direct large-scale competitor across the same product categories that Greer/Stallergenes Greer competes in.
• Biomay: Austrian allergen manufacturer producing recombinant and natural allergen extracts for diagnosis and immunotherapy, comparable as a specialist source-materials and extract supplier.
• Antigen Laboratories: US-based allergen extract manufacturer serving allergists with diagnostic and therapeutic extracts, directly comparable to Greer's Human Allergy line in the same domestic channel.
• Indoor Biotechnologies: Specialist producer of high-purity allergenic source materials and recombinant allergens for diagnostics and research, comparable as a Source Materials supplier in the upstream value chain.
• Allergy Therapeutics: UK-based specialty biopharmaceutical company developing and commercialising allergy immunotherapy vaccines and diagnostics for both human and veterinary use, directly comparable in product, modality, and customer base.

Emerging players

• DBV Technologies: Clinical-stage biotech developing epicutaneous immunotherapy (Viaskin patch) for food allergies; competes indirectly by addressing the same underlying allergy population with a non-extract modality.
• Aimmune Therapeutics (Nestlé Health Science): Developer of oral immunotherapy for food allergies (Palforzia), acquired by Nestlé Health Science; represents the shift to non-extract AIT modalities that may compete for the same prescriber relationships.

Broad incumbents

• HollisterStier Allergy (Johnson & Johnson): US-based allergen extract manufacturer operating under J&J's broader portfolio; competes with Greer/Stallergenes Greer for share of US allergists prescribing subcutaneous immunotherapy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/greer-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greer Laboratories